Ayata Gamze, Gordon Fredric D, Lewis W David, Pomfret Elizabeth, Pomposelli James J, Jenkins Roger L, Khettry Urmila
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Hum Pathol. 2002 Nov;33(11):1098-104. doi: 10.1053/hupa.2002.129419.
The incidence of cryptogenic cirrhosis (CC) has decreased since the discovery of hepatitis C virus (HCV), still the etiology in 5% of cases with cirrhosis remains unresolved. Our aims were to define the clinicopathologic features of CC at liver transplantation (LT), evaluate the post-LT course with outcome and define the possible pathogenetic mechanisms. 27/534 LT recipients (5%) over a period of 16.5 years were entered in the LT database as cases of CC. A detailed analysis of pre- and post-LT clinical and all liver pathology specimens was performed. Based on clinicopathologic findings, a more definite diagnosis was possible in 23 of 27 (85%): Nonalcoholic steatohepatitis (NASH) in 9 (33%), autoimmune liver disease (AILD) in 6 (22%), alcoholic liver disease in 4, secondary biliary cirrhosis in 2 and 1 each of hepatitis C and portal venopathy. 4/27 cases remained unresolved. In the NASH group, native livers had focal steatosis, Mallory's hyalin, glycogenated hepatocytic nuclei, high-grade inflammation, and 3+ bile duct proliferation. Large cell dysplasia was more common in this group compared to other patients. Two patients had recurrence of NASH after LT. In AILD group native livers had little or no bile duct proliferation. Two patients had recurrence in AILD group. Of 27 patients 19 are alive (70%) with a follow-up of 407-3647 days. Based on the study results, the following conclusions were reached: (1) CC results from varying etiologies, which can be defined by a careful clinicopathologic analysis in a majority (85%) of cases; (2) Nonalcoholic steatohepatitis (33%) and AILD (22%) are the common underlying causes of CC; and (3) Post-LT outcome for CC is disease dependent with, recurrent disease seen in both nonalcoholic steatohepatitis (22%) and autoimmune liver disease (33%).
自丙型肝炎病毒(HCV)被发现以来,隐源性肝硬化(CC)的发病率有所下降,但仍有5%的肝硬化病例病因不明。我们的目的是确定肝移植(LT)时CC的临床病理特征,评估LT后的病程及预后,并确定可能的发病机制。在16.5年的时间里,27例(5%)LT受者(共534例)被录入LT数据库,诊断为CC。对LT前后的临床情况及所有肝脏病理标本进行了详细分析。根据临床病理结果,27例中有23例(85%)得以明确诊断:9例(33%)为非酒精性脂肪性肝炎(NASH),6例(22%)为自身免疫性肝病(AILD),4例为酒精性肝病,2例为继发性胆汁性肝硬化,丙型肝炎和门静脉病各1例。27例中有4例病因仍未明确。在NASH组中,原肝有局灶性脂肪变性、马洛里透明变性、糖原化肝细胞细胞核、重度炎症以及3级胆管增生。与其他患者相比,该组大细胞异型增生更为常见。2例患者LT后出现NASH复发。在AILD组中,原肝几乎没有或没有胆管增生。AILD组中有2例患者复发。27例患者中有19例(70%)存活,随访时间为407 - 3647天。根据研究结果,得出以下结论:(1)CC由多种病因引起,多数(85%)病例可通过仔细的临床病理分析明确病因;(2)非酒精性脂肪性肝炎(33%)和AILD(22%)是CC的常见潜在病因;(3)CC患者LT后的预后取决于疾病类型,非酒精性脂肪性肝炎(22%)和自身免疫性肝病(33%)均可出现疾病复发。